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maturation markers and produced pro-inflammatory 
cytokines in a dose-dependent way to the protamine–RNA 
complexes. This was dependent on endosomal acidifica-
tion and correlated partly with the uptake of protamine–
RNA complexes. Furthermore, both DC subsets induced T 
cell proliferation and IFN gamma secretion in a beneficial 
ratio to IL-10. These results indicate that protamine–RNA 
complexes can be used to stimulate human mDC and pDC 
ex vivo for use in immunotherapeutic settings.
Keywords Immunotherapy · pDC · mDC · TLR · 
Adjuvants · GMP
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Abstract Dendritic cells (DCs) are key in connecting 
innate and adaptive immunity. Their potential in induc-
ing specific immune responses has made them interesting 
targets for immunotherapeutic approaches. Our research 
group was the first to exploit the naturally occurring mye-
loid DCs (mDCs) and plasmacytoid DCs (pDCs) in thera-
peutic vaccination trials against melanoma. To develop pri-
mary DC subsets as an optimal vaccine, the identification 
of a clinically applicable adjuvant activating both subsets 
is required. Although the expression of pathogen recogni-
tion receptors differs distinctly between the DC subsets, 
both pDCs and mDCs can respond to single-stranded RNA 
(ssRNA) via Toll-like receptors 7 and 8, respectively. Since 
ssRNA is easily degraded by RNases, we stabilized anionic 
RNA by complexing it with the positively charged protein 
protamine. This leads to the formation of protamine–RNA 
complexes with varying features depending on ionic con-
tent. We subsequently investigated the immunostimulatory 
effect of complexes that formed various salt concentrations 
on purified DC subsets. Both mDCs and pDCs upregulated 
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ssRNA  Single-stranded RNA
TCR  T cell receptor
Th  T helper
TLR  Toll-like receptor
TNF  Tumor necrosis factor
Introduction
Dendritic cells (DCs) connect the innate and the adaptive 
immune systems. In blood, three major DC subsets are 
found: CD1c+ (BDCA1+) myeloid DCs (mDCs), CD141+ 
(BDCA3+) mDCs, and CD303 (BDCA2+) plasmacytoid 
DCs (pDCs) [1, 2]. After a DC has encountered an antigen, 
it matures and migrates to the adjacent lymph node, where 
it interacts with naïve T cells and initiates an antigen-spe-
cific immune response. The activation state of the DCs will 
influence the resulting adaptive response, spanning from 
tolerogenic to immunogenic [3]. To sense danger and to be 
able to initiate eradicating adaptive responses against anti-
gens, DCs are equipped with a wide range of pattern rec-
ognition receptors (PRRs) [4]. These receptors recognize 
danger-associated molecular patterns, such as conserved 
microbial structures or nucleic acids, which upon bind-
ing mature the DCs. The types of PRRs being engaged on 
the DCs have a great impact on the subsequent adaptive 
immune response.
There are several groups of PRRs, the first characterized, 
and so far the most studied group, are the Toll-like receptors 
(TLRs) [5]. These are transmembrane molecules expressed 
in hetero- or homodimers, either on the cell surface or in the 
endosomal compartment. Most innate immune cells express 
TLRs in various combinations, and the receptor family 
therefore poses as potential target for vaccine adjuvants. In 
addition to the naturally occurring ligands, several synthetic 
TLR ligand analogs have been developed.
Due to their unique ability to stimulate naïve T cells, 
DCs are often used in cell-based immunotherapy. The 
majority of DC-based clinical studies are performed with 
in vitro differentiated DCs, such as monocyte-derived DCs 
or cells generated from CD34+ progenitor cells [6–8]. Our 
research group is using pDCs [9] and CD1c+ DCs (Schrei-
belt et al. manuscript in preparation) in therapeutic vacci-
nation of melanoma patients, with promising results [9]. 
However, the stimuli used to mature these subsets are not 
purified PRR ligands, which are required for optimal acti-
vation of DCs [3]. Activation of PRRs such as TLRs will 
upregulate major histocompatibility complex (MHC) mole-
cules, co-stimulatory molecules, and prime DCs to produce 
T helper (Th) polarizing cytokines. These cytokines act on 
interacting antigen-specific T cells and skew the adaptive 
immune response toward a desirable phenotype, depending 
on initial stimuli [10]. The usage of strong DC activators, 
such as TLR ligands, as adjuvant in immunotherapy is 
therefore desirable.
For effective anti-tumor effects, a Th1 response with 
the ability to activate cytotoxic CD8+ T cells (CTLs) is 
required. This is induced by interleukin (IL) 12p70-pro-
ducing DCs, but can also be mediated by type I interfer-
ons (IFNs) [11, 12]. An inducer of IL-12p70 in mDCs is 
the TLR3 ligand poly I:C, while pDCs are secreting high 
levels of IFN-α in response to TLR9-activating CpG oligo-
nucleotides [13]. However, CpG has been shown to inhibit 
the effect of poly I:C, and using a combination of these two 
ligands in an adjuvant would most likely not be beneficial 
[14]. Instead, to prevent unforeseen cross-reactions, a stim-
ulus with the potency to activate both mDCs and pDCs is 
preferred. Additionally, a standardized protocol would also 
provide more flexibility in combining the two subsets in 
future studies and clinical trials. Cross-talk between mDCs 
and pDCs has been shown to be important both in anti-viral 
responses and during anti-cancer immunotherapy [15]. We 
hypothesize that using both subsets will result in a broader 
and multifaceted immune reaction in response to DC-based 
immunotherapy.
One obstacle for using one stimulus for both DC sub-
sets is that they do not express an overlapping repertoire of 
TLRs [13]. However, TLR7 and TLR8, expressed by pDCs 
and mDCs, respectively, can respond to the same type of 
ligand—single-stranded RNA (ssRNA) [5, 16]. Unpro-
tected ssRNA is a suboptimal ex vivo DC stimulator due to 
its sensitivity to RNases, RNA-degenerating enzymes pre-
sent in, e.g., serum [17]. So far, there is no ligand targeting 
both TLR7 and TLR8 approved for clinical use other than 
topical application [18]. By using the polybasic protein 
protamine, ssRNA can be stabilized in an immunostimula-
tory protamine–RNA complex [19–21]. In this study, we 
have evaluated the effect of protamine–RNA complexes, 
consisting of clinically applicable reagents, on purified DC 
subsets. Both pDCs and CD1c+ DCs upregulated matura-
tion markers and secreted pro-inflammatory cytokines 
upon treatment with protamine–RNA. This was dependent 
on endosomal maturation and the ability of the complexes 
to engage TLR signaling. Furthermore, protamine–RNA-
stimulated DCs induced T cell proliferation and antigen-
specific T cell activation, making the complexes a highly 
interesting stimulus for future vaccination trials based on 
primary human DC subsets.
Materials and methods
Reagents
As ligands for TLR3, 7/8, and 9, polyinosine-polycytidylic 
acid (poly I:C, 20 µg/ml; Sigma-Aldrich, St Louis, MO), 
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imidazoquinoline (R848, 4 µg/ml; Axxora, San Diego, 
CA), and CpG class C DNA oligodeoxynucleotides (CpG, 
5 µg/ml; Axxora) were used. To inhibit endosomal acidifi-
cation, chloroquine (20 µM; Invivogen, Toulouse, France) 
was pre-incubated with the cells 1 h before addition of the 
stimulus. To capture cytokines intracellularly, brefeldin A 
(10 μg/ml; Sigma-Aldrich) was added to the cultured cells 
12 h before analysis.
Preparation of protamine–RNA complexes
To form the protamine–RNA complexes, protamine (pro-
taminehydrochloride MPH 5000 IE/ml; Meda Pharma BV, 
Amstelveen, the Netherlands) was diluted to 0.5 mg/ml in 
water, 25 mM NaCl, or 50 mM NaCl and mixed 2:1 with 
ca 2-kbp-long single-stranded mRNA (coding for gp100, 
tyrosinase, or CEA, 0.5 mg/ml; CureVac GmbH, Tübingen, 
Germany). After extensive mixing, the mix was incubated 
for 5–10 min at room temperature and added to the cell cul-
tures in the indicated concentrations. Dynamic light scatter-
ing and zeta potential of the complexes were measured in 
a Malvern Zetasizer 2000 (Malvern Instruments Ltd, Mal-
vern, UK).
For the uptake experiments, the formed complexes were 
diluted 1:1 in the Fixable Viability Dye eFluor 780 (live–
dead dye, 200X; eBioscience, San Diego, CA) and incu-
bated at room temperature for 15 min. The reaction was 
stopped by addition of 10 % human serum or RNase-free 
bovine serum albumin and the labeled complexes were 
added to DCs. The DC viability was investigated by adding 
propidium iodide (500 ng/ml; Biolegend, San Diego, CA) 
just before acquisition.
Cell isolation and culture
Peripheral blood mononuclear cells (PBMCs) were isolated 
from buffy coats of healthy individuals taken after informed 
consent using Ficoll density centrifugation (Lymphoprep; 
Axis-Shield PoC AS, Oslo, Norway). For CD1c+ DC 
and pDC isolation from PBMCs, microbead isolation kits 
were used (BDCA1+ DC and BDCA4+ DC isolation kits; 
Miltenyi Biotec, Bergisch-Gladbach, Germany), resulting 
in up to 95 % purity. During purification of CD1c+ DC, 
CD14+ cells were depleted using CD14 microbeads (Milte-
nyi Biotec). Prior pDC isolation, peripheral blood leuko-
cytes (PBLs) were prepared by depleting monocytes from 
PBMCs either by plastic adherence or with CD14 microbe-
ads. Isolated cells were cultured overnight at 5 × 105 cells/
ml in X-VIVO-15 medium (Cambrex, Verviers, Belgium) 
supplemented with 2 % human serum (Sanquin, Nijmegen, 
the Netherlands). For unstimulated pDCs, recombinant 
human IL-3 (10 ng/ml; Cellgenix, Freiburg, Germany) 
was added as a survival factor. T cells were isolated using 
negative microbead selection (Miltenyi Biotec), resulting in 
up to 98 % purity.
293XL-hTLR8 HEK cell lines (InvivoGen) expressing 
endosomal TLR8 were cultured in DMEM with GlutaMAX 
(Life Technologies, Carlsbad, CA) supplemented with 
10 % fetal calf serum (FCS), 1 % antibiotic antimycotic 
(AA; PAA laboratories, Pasching, Austria), and blasticidin 
(10 µg/ml; InvivoGen) as selection antibiotic.
Jurkat E6.1 fl296 cells transfected with T cell receptor 
(TCR) v-beta14, as previously described [22, 23], were 
cultured in RPMI (Life Technologies) supplemented with 
10 % FCS and 0.5 % AA.
Stimulation with protamine–RNA complexes
All DC experiments were performed in X-VIVO-15 in 
the presence of 2 % human serum. For DC co-culture 
experiments, Jurkat cells were diluted in X-VIVO-15 
supplemented with 2 % human serum. 293XL-hTLR8 
HEK cell lines were stimulated in DMEM with Glu-
taMAX supplemented with 10 % FCS 1 % AA and blas-
ticidin. protamine–RNA complexes were made fresh 
5–10 min before addition to cell culture. R848 was used 
as TLR7/8 control.
Flow cytometry
The purity of freshly isolated CD1c+ DC and pDC was 
assessed by staining with the following primary monoclo-
nal antibodies (mAbs): anti-CD19-FITC (Dako, Glostrup, 
Denmark), anti-BDCA1-PE, anti-BDCA-2-APC (both 
Miltenyi Biotec), and anti-CD14-PerCP (BD Biosciences, 
San Jose, CA). The purity of freshly isolated T cells was 
determined by staining with mAb anti-CD20-FITC, 
anti-CD3-PE, and anti-CD56-APC (all BD Biosciences). 
For human leukocyte antigen (HLA) phenotyping, the mAb 
anti-HLA-A2-PE (BD Biosciences) was used. The samples 
were acquired in a FACSCalibur (BD Biosciences).
To stain for DC maturation, the following mAbs were 
used: anti-HLA-ABC-PE, anti-HLA-DR-FITC, anti-CD80-
PE or PE-Cy7, anti-CD86-APC (all BD Biosciences), anti-
HLA-DR-PerCP (Biolegend), and anti-CD40-PE (Immu-
notech, Marseille, France). To stain for C-C chemokine 
receptor type 7 (CCR7), anti-CCR7 mouse IgG2a (R&D 
Systems, Minneapolis, MN), and goat anti-mouse-IgG2a-
Alexa647 or Alexa488 (Life Technologies) were used. 
Dead cells were detected with eFluor 780 live–dead cell 
marker (2000X). The samples were measured on a FACS-
Calibur or a CyAn ADP (Beckman Coulter, Fullerton, CA).
To assess cytokine production by T cells after stimula-
tion with DCs, co-cultures were stained with eFluor 780 
live–dead cell marker and the following mouse mAbs: 
anti-CD3-PE and anti-IFN-γ-APC (all BD Biosciences) or 
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anti-IgG1-APC (eBioscience) as isotype control (data not 
shown). Prior to IFN-γ staining, cells were fixed and per-
meabilized using a cytofix/cytoperm kit (BD Biosciences). 
To exclude DC from the gated cell population, co-cultures 
were also stained with anti-BDCA2-PE-Cy7 (Biolegend) or 
APC (Miltenyi Biotec), and anti-CD11c-PE-Cy7. The acti-
vation of Jurkat cells was assessed with eFluor 780 live–
dead dye, anti-CD3-FITC, and anti-CD69-APC (both BD 
Biosciences). The samples were measured on a CyAn ADP.
All analyses were performed using FlowJo Software 
(TreeStar Inc, Ashland, OR). Only viable cells gated on the 
specific population in forward-side scatter were assessed. 
The results are depicted either as percentage positive cells 
or as geometric mean fluorescence intensity (MFI) normal-
ized to the negative control to compensate for use of differ-
ent flow cytometers and fluorophores.
Cytokine detection
Supernatants of stimulated cells were taken at indicated 
time points and analyzed with standard sandwich ELISAs 
detecting IL-12p70, IFN-γ (both from Thermo Scientific, 
Waltham, MA), IFN-α (Bender Medsystems, Vienna, Aus-
tria), IL-5, IL-10 (both from eBioscience), tumor necrosis 
factor (TNF) α, and IL-8 (both from BD Biosciences).
Mixed lymphocyte reaction
The ability of stimulated DCs to induce T cell proliferation 
was investigated in a mixed lymphocyte reaction (MLR). 
Allogeneic PBLs or T cells were stained with carboxy-
fluorescein diacetate succinimidyl ester (CFSE, 5μM; 
Life Technologies) for 10 min; thereafter, the reaction was 
stopped by protein blocking using FCS. Overnight-acti-
vated DCs were cultured with CFSE-labeled cells in a 1:10 
ratio for 3–5 days. As a control, Staphylococcal enterotoxin 
B (SEB, 5 μg/ml; Sigma-Aldrich) was used.
Antigen‑presentation assay
Donors were screened for HLA-A0201, and DCs from pos-
itive donors were stimulated with indicated stimuli, pulsed 
with 10 µM specific peptide (gp100280–288) or irrelevant 
peptide (tyrosinase369-376), and co-cultured 1:2 with Jurkat 
E6.1 fl296 cells expressing the TCR-v-beta14 overnight.
Statistical analyses
To detect statistical significant differences between indi-
cated groups, Wilcoxon matched-pair signed-rank tests or t 
tests were performed on raw data and paired measurements 
and analyzed with GraphPad Prism (GraphPad, La Jolla, 
CA). Values of p < 0.05 were considered significant.
Results
Protamine complexed with RNA forms positively 
charged particles with varying size depending on salt 
concentration
It has long been known that negatively charged RNA 
has the ability to bind strongly to substances with posi-
tive charge [24]. A protein that has been used to complex 
nucleic acids is the polybasic protein protamine [17, 21, 
25]. The physical characteristics of complexes formed 
when mixing anionic RNA to cationic protamine is depend-
ent on the ratio between the components and on ionic con-
tent [26]. Since CD1c+ DCs and pDCs differ in their ability 
to take up and respond to particles [27] and express differ-
ent TLRs [4], we produced protamine–RNA complexes in a 
ratio of 2:1 in 0, 25, or 50 mM NaCl and investigated their 
size by dynamic light scattering (Fig. 1a–b). The complexes 
formed in water or low salt concentration were <200 nm 
in diameter, while higher salt concentration formed com-
plexes of >500 nm. The particle charge remained relatively 
constant between the formulations, ranging between 30 and 
40 mV (Fig. 1c).
Protamine–RNA complexes mature both CD1c+ DCs 
and pDCs in a concentration‑dependent manner
To evaluate the ability of RNA complexed to protamine to 
activate DCs, we formulated protamine–RNA complexes 
with different salt conditions (Fig. 2). Purified DCs were 
cultured overnight with concentrations ranging from 1.5 to 
15 µg/ml of protamine–RNA complexes formed in either 0, 
25, or 50 mM NaCl. As a control for cell stimulation, the 
TLR7/8 ligand R848 was used. Viability and expression of 
maturation markers were investigated. Unstimulated pDCs 
do not survive ex vivo; therefore, IL-3-treated cells were 
used as a negative control [28].
The viability of the CD1c+ DCs was not affected by pro-
tamine–RNA complexes, while a slight decrease in viabil-
ity was detected for pDCs (Fig. 2a). To investigate whether 
protamine–RNA complexes had a direct toxic effect on 
the pDCs, IL-3 was added to the cultures and the viabil-
ity examined. There was no difference in viability between 
R848-treated pDCs and protamine–RNA-treated pDCs. 
IL-3 had a favorable effect on pDC viability in the tested 
conditions (Supplementary Fig. 1a).
Next, the ability of the protamine–RNA complexes to 
mature DCs was investigated. For the CD1c DCs, all com-
plexes increased the expression of MHC class I, while 
only smaller complexes had this effect on pDCs (Fig. 2b). 
Protamine–RNA-induced upregulation of HLA-DR was 
detected on the CD1c+ DCs, while on the pDCs, IL-3 alone 
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increased HLA-DR expression and no additive effect of the 
complexes was observed. All complexes induced upregula-
tion of maturation marker CD86 on CD1c+ DCs, with the 
strongest effect detected for the large complexes formed in 
the presence of high salt concentrations (Fig. 2c). For the 
pDCs, an opposite pattern was seen; the highest upregula-
tion of CD86 was induced by protamine–RNA complexes 
formed without salt (Fig. 2c).
Since the viability of the DCs did not differ between the 
protamine–RNA concentrations used and a dose-dependent 
upregulation of maturation markers and MHC complexes 
was observed, we performed additional experiments with 
the highest concentration tested. This concentration also 
led to upregulation of additional activation markers, such 
as CD40, CD80, and CCR7 (Supplementary Fig. 1b, c). 
Unprotected RNA has previously been shown to activate 
an antigen-specific immune response upon intranodal injec-
tion [29]. However, addition of RNA or protamine without 
complexing did not lead to DC maturation in our hands 
(data not shown).
Dendritic cells stimulated with protamine–RNA 
complexes release high levels of pro‑inflammatory 
cytokines
The cytokine profile of activated DCs plays an important 
role in the skewing of naïve T cells. We therefore compared 
the release of pro-inflammatory cytokines from purified 
DCs stimulated overnight with protamine–RNA complexes 
formed in water or increasing salt concentrations. All three 
protamine–RNA complex formations induced fivefold to 
tenfold more IL-12p70 than the positive control poly I:C 
(Fig. 3a). pDCs secreted comparable levels of IFN-α upon 
stimulation with the positive control CpG-C and prota-
mine–RNA complexes (Fig. 3b). In accordance with the 
results in Fig. 2, the smaller protamine–RNA complexes 
induced the strongest response in pDCs.
An important regulator of IL-12 production is IL-10 
[30]. IL-10 production by both CD1c+ DCs and pDCs 
was observed after stimulation with poly I:C and CpG-
C, respectively. Significantly lower amounts of IL-10 
were observed in the protamine–RNA-stimulated cultures 
(Fig. 3c). Both DC subsets secreted significant amounts of 
TNF-α upon protamine–RNA treatment (Fig. 3c).
Protamine–RNA complexes induce TLR signaling 
via the endosomal compartment of DCs
When investigating the cytokine profile of protamine–
RNA-stimulated DCs, a shift toward NFκB-driven 
responses was seen with increasing salt concentrations, 
while a type I IFN response was seen when the complexes 
were formed in water. We therefore investigated what 
mechanism was driving the DC responses. The activation 
via TLR7 in response to protamine–RNA complexes is pre-
viously shown in a murine setting [20],
We confirmed that the complexes had the ability to signal 
via TLRs by testing the effect of the complexes on TLR8-
expressing HEK cells. TLR8-expressing or non-transduced 
HEK cells were cultured overnight with the different prota-
mine–RNA complexes, and IL-8 was measured in the super-
natant. While no IL-8 was secreted from TLR8 non-express-
ing cells (data not shown), all protamine–RNA complexes 
were able to induce IL-8 production in TLR8-expressing 
HEK cells, with the complexes formed with high salt con-
centrations inducing the highest response (Fig. 4a).
To activate TLR7/8, the ligand should reach the 
endosomes, where signaling is initiated by lowering the 
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Fig. 1  Concentration of NaCl determines size, but not charge, when 
forming protamine–RNA complexes. protamine–RNA complexes (pR) 
were formed in water, 25 mM NaCl, or 50 mM NaCl, particle size was 
evaluated by dynamic light scattering (a, b), and the zeta potential was 
investigated to determine the charge of the complexes (c)
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complexes by DCs, protamine–RNA complexes were incu-
bated with a fixable live–dead dye. This dye binds nucleic 
acids, and its activity can be stopped by addition of a pro-
tein blocker. Protamine–RNA complexes labeled with the 
live–dead dye, the live–dead dye alone, or medium alone 
were added to CD1c+ DCs and pDCs. After culturing for 
1 h, the binding and uptake was assessed by flow cytom-
etry (Fig. 4b, c). In some experiments, propidium iodide 
was used as a viability stain to confirm that the labeled 
complexes were bound to viable DCs (data not shown). 
Approximately 15 % of the CD1c+ DCs associated with 
labeled complexes after 1 h of culture. For pDCs, the small-
est complexes were most efficiently bound, although also 
the larger complexes formed in high NaCl concentrations 
associated stronger with pDCs as compared to CD1c+ DCs.
Next, we investigated the importance of endosomal mat-
uration for protamine–RNA-induced DC activation. Endo-
somal acidification was prevented using chloroquine 1 h 
before addition of the complexes. The TLR ligands poly 
I:C and CpG-C were used as controls for the efficacy of 
chloroquine treatment, while R848, previously shown to 
be able to induce DC activation despite chloroquine treat-
ment [31], was used as a positive control. The increase in 
CD86 and CD80 expression was inhibited when the chlo-
roquine pre-treated DCs were cultured with the complexes, 
as compared to untreated cells (Fig. 4d and Supplementary 
Fig. 2a). The secretion of IL-12p70 and IFN-α was absent 
in chloroquine-treated CD1c+ DCs and pDCs, respectively, 
as well as TNF-α (Supplementary Fig. 2b). Although the 
viability of the CD1c+ DCs was not strongly affected by the 
addition of chloroquine, pDCs were deprived of their sur-
vival signal and a decreased viability was seen in all groups 
except for the IL-3- or R848-treated cells (Supplementary 
Fig. 3  Pro-inflammatory 
cytokines are secreted by 
protamine–RNA-stimulated 
DCs. The concentrations of 
pro-inflammatory cytokines in 
supernatants taken from CD1c+ 
DCs and pDCs stimulated 
overnight with medium or IL-3, 
R848, poly I:C or CpG-C, or 
15 µg/ml protamine–RNA 
complexes (pR) formed in 0, 25, 
or 50 mM NaCl were measured 
by ELISA. The concentra-
tion ± SEM of IL-12p70 (a) 
from 9 to 11 CD1c+ DC donors, 
IFN-α (b) from 6–10 pDC 
donors, or IL-10 and TNF-α 
(c) from 5-11 CD1c+ DC and 
4–8 pDC donors is depicted. 
Wilcoxon matched-pair signed-
rank tests were performed 
between indicated groups and 
are indicated by *(p < 0.05), 















































































































































































Fig. 2  Protamine–RNA complexes are well tolerated by DCs and 
induce upregulation of maturation markers and MHC complexes. 
Purified CD1c+ DCs and pDCs were cultured 18–24 h with 15, 7.5, 
or 1.5 µg/ml of protamine–RNA complexes (pR) formed in 0, 25, or 
50 mM NaCl. Untreated CD1c+ DCs or IL-3 treated pDCs were used 
as negative controls, while R848 was used as a control for TLR7/8 
stimulation and poly I:C and CpG-C were used as positive controls 
for CD1c+ DCs or pDCs, respectively. a The cell viability was deter-
mined by flow cytometry. The mean percentage ± SEM of cells 
negative for live–dead marker from 7–8 CD1c+ DC donors and 6–8 
pDC donors is depicted. b, c The relative expression of MHC class 
I and HLA-DR (b) and CD86 (c) on viable cells was calculated by 
normalizing the MFI values for each donor against the negative con-
trol. The fold increase ± SEM of 6–10 CD1c+ DC and pDC donors 
is depicted. Wilcoxon matched-pair signed-rank tests were performed 
on raw data, comparing against negative control, and are indicated by 
*(p < 0.05), **(p < 0.01), ***(p < 0.001), or NS (non-significant)
◂
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Fig. 4  Effect of protamine–
RNA complexes is TLR medi-
ated. a TLR8 expressing HEK 
cells were cultured overnight 
with medium alone, R848, or 
protamine–RNA complexes 
(pR) formed in 0, 25, or 50 mM 
NaCl. The mean results ± SEM 
from three individual experi-
ments run in triplicate or 
duplicate is depicted. T tests 
were performed on pooled data 
between indicated groups and 
are indicated by *(p < 0.05) or 
NS (non-significant). (b‑c) DCs 
were cultured for 1 h with live–
dead marker-labeled protamine–
RNA complexes (pR) formed in 
0, 25, or 50 mM NaCl or with 
live–dead marker alone and ana-
lyzed by flow cytometry. Per-
centages of protamine–RNA-
positive cells were calculated 
on gated DCs and depicted as 
a representative figure (b) or as 
the mean uptake ± SEM from 7 
CD1c+ DC and pDC donors (c). 
Wilcoxon matched-pair signed-
rank tests were performed 
between indicated groups and 
are indicated by *(p < 0.05) or 
**(p < 0.01). d CD1c+ DCs 
and pDCs were pre-incubated 
for 1 h with chloroquine before 
the addition of medium alone 
or IL-3, R848, poly I:C or 
CpG-C, or protamine–RNA 
complexes (pR) formed in 0, 25, 
or 50 mM NaCl. The upregula-
tion of CD86 was measured by 
flow cytometry after over-
night culture and the relative 
expression was calculated by 
normalizing the MFI values for 
each donor against the negative 
control. Fold increase ± SEM 
of 4–5 CD1c+ DC and 3–5 
pDC donors is depicted. T tests 
were performed on raw data 
between indicated groups and 
are indicated by *(p < 0.05), 
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Fig. 2c), further demonstrating the importance of the endo-
somal route in response to protamine–RNA complexes.
Protamine–RNA‑stimulated DCs induce proliferation 
and activation of T cells
After characterizing the effects of protamine–RNA on pri-
mary DCs, the subsequent T cell response induced by acti-
vated DCs was investigated. Proliferation of CFSE-labeled 
PBLs was measured in an allogeneic setting. The percent-
age of dividing CD3+ cells was determined 5 days after 
addition of protamine–RNA-activated DCs. As a positive 
control for proliferation, SEB was added (data not shown). 
R848- and protamine–RNA-treated CD1c+ DCs induced 
comparable proliferation of T cells, which was significantly 
higher than untreated DCs (Fig. 5a). Stimulated pDCs also 
induced a proliferative response in T cells comparable to 
IL-3-treated cells (Fig. 5a).
Fig. 5  T cell proliferation and 
IFN-γ production is induced 
by protamine–RNA-stimulated 
DCs. DCs were cultured with 
medium alone or IL-3, R848, 
or protamine–RNA complexes 
(pR) formed in 0, 25, or 50 mM 
NaCl. CFSE-labeled allogenic 
PBLs or T cells were added 
after overnight culture. a The 
dilution of CFSE-labeled 
PBLs was measured on 
CD3+CD11c−BDCA2− cells 
by flow cytometry on day 5. 
Cultured, unstimulated PBLs 
were used as reference. The 
mean percentage proliferating 
cells ± SEM of 6 CD1c+ DC 
and pDC donors is depicted. 
b The expression of IFN-γ 
and IL-10 in day 2 DC:PBL 
co-cultures was measured 
with ELISA. Mean concen-
tration ± SEM from 5 to 6 
CD1c+ DC and pDC donors 
is depicted. c, d Intracel-
lular IFN-γ was measured in 
CD3+CD11c−BDCA2− T cells 
cultured for 5 days either alone 
or with DCs stimulated with 
medium or IL-3, R848, or pR 
complexes. Results are depicted 
as the mean percentage IFN-γ+ 
cells ± SEM from 6 CD1c+ DC 
and pDC donors (c) or as a rep-
resentative figure (d). Wilcoxon 
matched-pair signed-rank tests 
were performed between indi-
cated groups and are indicated 
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To investigate the response of the stimulated T cells, 
the release of cytokines was measured. Supernatants were 
taken at day 2 of DC:PBL co-cultures, and IFN-γ, IL-10, 
and IL-5 were measured. Protamine–RNA-stimulated 
pDCs induced more IFN-γ than IL-3-treated cells and in 
similar quantities as protamine–RNA-stimulated CD1c+ 
DCs (Fig. 5b). In addition, the PBLs produced less IL-10 
when co-cultured with protamine–RNA-stimulated pDCs 
than with IL-3 treated cells. For CD1c+ DCs, the negative 
control induced only low levels of IFN-γ and IL-10, while 
protamine–RNA-treated DCs stimulated elevated levels of 
both cytokines (Fig. 5b). No IL-5 secretion was detected 
(data not shown). This supports that T cells activated by 
protamine–RNA-stimulated DCs display Th1 characteris-
tics and not a regulatory profile. To confirm this, the MLR 
experiment was repeated with purified allogeneic T cells, 
which were investigated for intracellular IFN-γ production 
(Fig. 5c, d). T cells co-cultured with DCs activated by the 
smaller complexes produced significantly more IFN-γ than 
control cultures.
Antigen‑specific T cell responses are induced 
by protamine–RNA‑stimulated DCs
To test the ability of protamine–RNA-stimulated DC to 
present antigens to T cells, HLA-A0201+ DCs were pulsed 
with either gp100280–288 short peptide or irrelevant peptide 
and subsequently cultured with Jurkat cells transfected 
with the TCR-v-beta14 receptor recognizing gp100280–288 
in the context of HLA-A0201 (Fig. 6). The Jurkat cells are 
activated upon recognition of the specific antigen, inde-
pendent of co-stimulatory signals. A distinct upregulation 
of activation marker CD69 was detected in Jurkat cells cul-
tured with gp100280-288-pulsed DCs, while irrelevant pep-
tide-pulsed DCs induced responses comparable to Jurkat 
cells cultured with the protamine–RNA complexes in the 
absence of DCs. Hence, protamine–RNA-treated pDCs and 
CD1c+ DCs both retain the ability to present specific anti-
gens to T cells.
Discussion
Our research group has recently focused on developing 
immunotherapeutic strategies based on primary DC sub-
sets, using different clinical activation protocols for mDCs 
and pDCs [8, 9]. In the pDC trial, Frühsommer-meningoen-
cephalitis (FSME) vaccine was used to activate the cells 
[9, 32], while unbeneficial responses were seen for CD1c+ 
DCs treated with FSME. Instead, GM-CSF has been used 
to activate this DC population, which does not efficiently 
activate pDCs to produce type I IFNs (Schreibelt et al., 
manuscript in preparation) [8]. The activation status of DCs 
is an important factor for the subsequent adaptive immune 
responses. To induce full activation of DCs, signaling via 
PRRs such as TLRs is necessary [3, 33]. Although a vast 
number of TLR ligands have been developed, only a few are 
approved for clinical use. Currently, there is no TLR ligand 
available that can be used to activate both mDCs and pDCs 
which is produced according to good manufactoring prac-
tice (GMP) [18]. Therefore, we have used the clinical grade 
reagents protamine and mRNA to compile a TLR7/8 ligand 
with the ability to activate both pDCs and CD1c+ DCs.
The immunopotent effect of ssRNA complexed to cati-
onic proteins has previously been described [19, 20, 34], 
and the ionic content of the solution in which the com-
plexes are formed has shown to affect their features and 
size [26]. Here, we have investigated the stimulatory 
effect of protamine–RNA complexes formed either in 
water or in increasing salt concentrations. Water or low 
salt concentrations formed smaller complexes, while high 
salt concentrations mediated formation of complexes 

















































































Fig. 6  Protamine–RNA-stimulated DCs can induce antigen-specific 
T cell responses. HLA-A0201+ DCs were pulsed with gp100280–288 
short peptide or irrelevant peptide, stimulated with protamine–RNA 
complexes (pR) formed in 0, 25, or 50 mM NaCl, and co-cultured 
overnight with Jurkat cells expressing the TCR-v-beta14 receptor 
specific for the gp100280–288 peptide in the context of HLA-A0201. 
The upregulation of CD69 on Jurkat cells was assayed with flow 
cytometry. The mean percentage of CD69 expression ± SEM on Jur-
kat cells co-cultured with 6 CD1c+ DC and pDC donors is depicted
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primary pDCs and CD1c+ DCs, the two subsets responded 
differently. All three complex formulations could stimu-
late CD1c+ DCs to upregulate maturation markers, MHC 
complexes, and pro-inflammatory cytokine production, 
although highest responses were seen with the larger 
complexes. Oppositely, pDCs fully matured after addition 
of the smaller complexes and not consistently with the 
complexes formed in high salt concentrations. This might 
be due to the inability of pDCs to efficiently engulf larger 
particles [27]. Indeed, when comparing the ability to bind 
and take up protamine–RNA complexes, pDCs associ-
ated significantly better with smaller complexes than with 
the large ones, while CD1c+ DCs associated with the 
different complexes equally. However, pDCs did associ-
ate with the large complexes, indicating that the binding 
and uptake is not the only factor regulating the cellular 
responses toward the complexes. For instance, the larger 
protamine–RNA complexes might be stronger ligands 
for TLR8, while smaller complexes are more efficient for 
TLR7 stimulation. This phenomenon has previously been 
described for synthetic TLR7/8 ligands [35, 36]. Further-
more, a difference in proteolytic cleavage between TLR7 
and TLR8 was recently demonstrated [37]. In addition, 
the observed shift from a type I IFN-mediated response 
toward a NFκB-driven response has been reported to dif-
ferentiate the responses mediated by TLR7 and TLR8 
activation [36]. Although positive responses were detected 
for all three types of complexes, the TLR8 expressing 
HEK cell line responded strongest to the largest ones. 
Nevertheless, despite weaker responses, pDCs treated 
with protamine–RNA complexes formed in high salt 
concentration were still viable without extra addition of 
IL-3, which is needed for the long-term culturing of non-
stimulated pDCs [28]. This indicates that even the larger 
complexes have the ability to provide a survival signal, 
but not necessarily fully activate pDCs. The decrease in 
pDC viability upon inhibition of endosomal acidification 
further supports this hypothesis.
To act as an effective adjuvant, a functional activation 
of relevant adaptive responses must be induced by DC 
treated with the stimulus. Protamine–RNA-stimulated DCs 
indeed induced proliferation of T cells. For CD1c+ DCs, a 
significant difference was observed between unstimulated 
and stimulated DCs. Addition of the survival factor IL-3 
to pDCs resulted in a high proliferation of PBLs, most 
likely due to an IL-3-induced upregulation of antigen-
presenting molecules. We therefore investigated the acti-
vation of the co-cultured cells to determine what kind of 
adaptive response protamine–RNA-treated DCs induced. 
An increase in IFN-γ production could be detected in both 
CD1c+ DC and pDC co-cultures, where T cells stimulated 
with protamine–RNA-treated DCs produced the highest 
levels of the cytokine.
In addition to inducing IFN-γ-producing T cells, an 
antigen-specific immune response must also be induced 
by the activated DCs. In our vaccination setting, stimu-
lated DCs are pulsed externally with peptide antigens 
[8, 9, 38]. Protamine–RNA-treated DCs induced an anti-
gen-specific response when pulsed with the gp100280–288 
HLA-A0201-binding peptide. IL-3-treated pDCs gave 
stronger results than both protamine–RNA complexes and 
R848 treatment, probably due to the elevated expression 
of antigen-presenting molecules, and it should be noted 
that this assay is not dependent on the activation status 
of the APC but rather on their ability to present peptide 
antigens.
To conclude, protamine–RNA complexes have the ability 
to induce maturation of pDCs and CD1c+ DCs via endoso-
mal-dependent pathways, most likely via ssRNA-mediated 
activation of TLR7 and TLR8. For CD1c+ DCs, the highest 
responses were observed with complexes of larger size, but 
significant upregulation of maturation markers, MHC mol-
ecules, and pro-inflammatory cytokines was detected also 
for the smaller complexes. Importantly, protamine–RNA 
complexes induced release of the Th1-skewing cytokine IL-
12p70 from CD1c+ DCs, making the stimulus highly inter-
esting when an anti-cancer response is desired. Also pDCs 
responded to protamine–RNA complexes, but for this subset 
smaller complexes, formed in water or low salt concentra-
tions, induced the strongest maturation as well as IFN-α 
production. Taken together, protamine–RNA complexes 
pose as an interesting adjuvant that can be GMP produced 
and used for activation of primary DCs in cell-based immu-
notherapy. Depending on the protocol, large complexes can 
be used to activate CD1c+ DCs, while small complexes are 
suitable to stimulate pDCs. Since the complexes are able to 
activate both CD1c+ DCs and pDCs, it also opens for the 
possibility of using protamine–RNA as a stimulus in a vac-
cine consisting of the two DC subsets together. Then the 
smaller complexes, with the ability to activate both pDCs 
and CD1c+ DCs, are recommended. High levels of IFN-α 
have been shown to activate cytotoxic responses in natu-
ral killer cells [39, 40], but have also been implemented in 
pDC:mDC cross-talk and Th1 responses [15, 41, 42]. 
The most prominent Th1-skewing cytokine, IL-12p70, 
is secreted by protamine–RNA-treated CD1c+ DCs. The 
combination of IFN-α and IL-12p70 derived from prota-
mine–RNA-stimulated pDCs and mDCs is a potent and 
multifaceted immunotherapy.
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